|
|
| | L-Lysine, L-phenylalanyl-L-threonyl-L-isoleucyl-L-seryl-L-alanyl-L-α-aspartyl-L-threonyl-L-seryl- Basic information |
| | L-Lysine, L-phenylalanyl-L-threonyl-L-isoleucyl-L-seryl-L-alanyl-L-α-aspartyl-L-threonyl-L-seryl- Chemical Properties |
| Boiling point | 1466.7±65.0 °C(Predicted) | | density | 1.341±0.06 g/cm3(Predicted) | | pka | 3.20±0.10(Predicted) |
| | L-Lysine, L-phenylalanyl-L-threonyl-L-isoleucyl-L-seryl-L-alanyl-L-α-aspartyl-L-threonyl-L-seryl- Usage And Synthesis |
| Uses | FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[1]. | | References | [1] Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88(3):1871-1877. DOI:10.1021/acs.analchem.5b04276 |
| | L-Lysine, L-phenylalanyl-L-threonyl-L-isoleucyl-L-seryl-L-alanyl-L-α-aspartyl-L-threonyl-L-seryl- Preparation Products And Raw materials |
|